Crinetics Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Crinetics Pharmaceuticals generated cash of -$166,307,000, which is less than the previous year. Cash used in financing activities reached the amount of $388,944,000 last year. Net change in cash is therefore $22,224,000.
Cash Flow
| 2016 | -5.46M | -190K | -53K |
|---|---|---|---|
| 2017 | -9.47M | -304K | 11.82M |
| 2018 | -19.45M | -119.45M | 170.19M |
| 2019 | -46.38M | 41.66M | 67K |
| 2020 | -62.02M | 217K | 114.57M |
| 2021 | -88.58M | -56.48M | 252.67M |
| 2022 | -115.20M | -173.98M | 121.96M |
| 2023 | -166.30M | -200.41M | 388.94M |
CRNX Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 33.97M | 201.19M | 93.58M | 40.82M | 45.47M | 14.19M | 12.15M | 17.86M |
Operating activities | ||||||||
Net income | -214.52M | -163.91M | -107.64M | -73.81M | -50.42M | -27.11M | -9.15M | -6.01M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 1.09M | 983K | 922K | 948K | 887K | 471K | 128K | 92K |
Stock-based compensation expense | 40.93M | 28.26M | 17.35M | 10.42M | 6.29M | 0 | 271K | 270K |
| Deferred income tax benefit | 40.93M | 28.26M | 17.35M | 10.42M | 6.29M | 0 | 271K | 270K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 14.64M | 10.99M | 6.29M | 2.72M | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | -6.29M | -2.72M | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 10.99M | 6.29M | 2.72M | 696K | 7.36M | 47K | 300K |
Cash generated by operating activities | -166.30M | -115.20M | -88.58M | -62.02M | -46.38M | -19.45M | -9.47M | -5.46M |
Investing activities | ||||||||
Purchases Of Investments | -532.85M | -329.81M | -125.40M | -135.59M | -108.13M | -118.39M | 0 | 0 |
Investments In Property Plant And Equipment | -4.68M | -1.65M | -436K | -186K | -492K | -1.05M | -304K | -190K |
Acquisitions Net | 195.72M | 34K | 422K | -227K | -1.22M | 0 | 0 | 0 |
Cash generated by investing activities | -200.41M | -173.98M | -56.48M | 217K | 41.66M | -119.45M | -304K | -190K |
Financing activities | ||||||||
Common Stock Issued | 369.01M | 117.24M | 249.54M | 114.28M | 0 | 0 | 12.03M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | -59K | 0 | 0 | -5K |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | -212K | -48K |
Cash used in financing activities | 388.94M | 121.96M | 252.67M | 114.57M | 67K | 170.19M | 11.82M | -53K |
Net Change In Cash | 22.22M | -167.22M | 107.60M | 52.76M | -4.64M | 31.28M | 2.04M | -5.71M |
Cash at end of period | 56.19M | 33.97M | 201.19M | 93.58M | 40.82M | 45.47M | 14.19M | 12.15M |
| Data source | Data source | Data source | Data source | Data source |